港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

来凯医药-B

16.240

-0.420-2.52%

成交量：908.60万

成交额：1.49亿

市值：66.26亿

市盈率：-20.96

高：17.390

开：17.000

低：15.900

收：16.660

52周最高：23.500

52周最低：4.200

股本：4.08亿

香港流通股本：4.08亿

量比：3.03

换手率：2.23%

股息：- -

股息率：- -

每股收益(LYR):-0.775

净资产收益率：-34.59%

总资产收益率：-19.92%

市净率：8.53

市盈率(LYR):-20.96

市销率: 1314.38

数据加载中...

总览公司新闻公告

中信证券：首予来凯医药-B(02105)“买入”评级目标价27港元

智通财经网

来凯医药-B盘中异动股价大跌5.87%报20.850港元

每日卖空追踪 | 来凯医药-B 06月11日卖空量成交1.85万股，卖空比例为0.32%

“吃药”行情继续，减肥药概念逆势大涨！

每日卖空追踪 | 来凯医药-B 06月09日卖空量成交8.85万股，卖空比例为0.74%

来凯医药-B尾盘涨超13% LAE102的I期SAD研究结果可观与礼来合作有望增强国际影响力

来凯医药-B盘中异动股价大涨5.34%

来凯医药-B06月06日获主力加仓122.3万元

来凯医药-B06月05日主力净流入5.3万元散户资金抛售

来凯医药-B盘中异动临近收盘股价大跌5.27%

围绕ActRII通路礼来与来凯医药(02105)将在2025ADA上“双龙戏珠”

2025ADA，减脂增肌风暴压不住了

每日卖空追踪 | 来凯医药-B 06月02日卖空量成交15.25万股，卖空比例为2.48%

来凯医药-B涨超9% LAE102 I期SAD试验结果可观将展示多项ActRII领域自主研发成果

来凯医药－Ｂ(02105)股价显著波动10.766%，现价港币$18.94

阿斯达克财经

每日卖空追踪 | 来凯医药-B 05月30日卖空量成交29.8万股，卖空比例为3.61%

来凯医药-B午前涨逾6% 公司将展示多项ActRII领域自主研发成果

【券商聚焦】中信建投首予来凯医药(02105)“买入”评级指其管线结构均衡未来可期

每日卖空追踪 | 来凯医药-B 05月29日卖空量成交7.5万股，卖空比例为2.23%

来凯医药-B(2105.HK)：与礼来达成临床合作公司减脂增肌赛道持续推进

中信建投证券

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02105/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02105","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02105\",,,,,undefined,":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":16.24,"timestamp":1756195699001,"preClose":16.66,"halted":0,"volume":9086000,"delay":0,"floatShares":408000000,"shares":408000000,"eps":-0.774704976038189,"marketStatus":"已收盘","change":-0.42,"latestTime":"08-26 16:08:19","open":17,"high":17.39,"low":15.9,"amount":148510298,"amplitude":0.089436,"askPrice":16.24,"askSize":268000,"bidPrice":16.2,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.7125131624130291,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1756258200000},"marketStatusCode":5,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":16.66,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":3.025278,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02105\",,,,,undefined,":{"symbol":"02105","floatShares":408000000,"roa":"-19.92%","roe":"-34.59%","lyrEps":-0.774705,"volumeRatio":3.025278,"shares":408000000,"dividePrice":0,"high":17.39,"amplitude":0.089436,"preClose":16.66,"low":15.9,"week52Low":4.2,"pbRate":"8.53","psRate":"1314.38","week52High":23.5,"institutionHeld":0,"latestPrice":16.24,"committee":-0.988868,"eps":-0.774704976038189,"divideRate":0,"volume":9086000,"delay":0,"ttmEps":-0.7125131624130291,"open":17,"prevYearClose":9.37,"prevWeekClose":17.19,"prevMonthClose":18.8,"prevQuarterClose":17.46,"fiveDayClose":17.98,"twentyDayClose":19.98,"sixtyDayClose":19.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02105\",params:#limit:5,,,undefined,":[{"date":"2025-08-13","symbol":"02105","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755048600000,"name":null,"time":"","dateTimestamp":1755014400000,"actualEps":null},{"date":"2025-03-24","symbol":"02105","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盘后","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-16","symbol":"02105","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723771800000,"name":null,"time":"盘后","dateTimestamp":1723737600000,"actualEps":null},{"date":"2024-03-26","symbol":"02105","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711416600000,"name":null,"time":"","dateTimestamp":1711382400000,"actualEps":null},{"date":"2023-08-24","symbol":"02105","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692840600000,"name":null,"time":"","dateTimestamp":1692806400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02105\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02105\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1754496000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02105\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02105","date":"2025-08-25","current":-24.093478,"percent":0.08818,"low":-30.832985,"twenty":-16.858738,"median":-8.407124,"eighty":-4.826315,"high":-1.640852,"avg":-10.791117,"sd":7.187702,"marketCap":6322695243},"quantilePoints":[{"date":"2023-06-30","current":-7.785551,"twenty":-6.73679,"median":-5.163648,"eighty":-3.590506,"marketCap":6577091901},{"date":"2023-07-07","current":-6.912426,"twenty":-7.480081,"median":-7.023469,"eighty":-6.753459,"marketCap":5828099229},{"date":"2023-07-14","current":-6.415246,"twenty":-7.354402,"median":-6.80281,"eighty":-6.620389,"marketCap":5484810921},{"date":"2023-07-21","current":-6.50021,"twenty":-7.00126,"median":-6.637911,"eighty":-6.415921,"marketCap":5531622963},{"date":"2023-07-28","current":-6.387862,"twenty":-6.910347,"median":-6.626959,"eighty":-6.393338,"marketCap":5430196872},{"date":"2023-08-04","current":-6.872048,"twenty":-6.916775,"median":-6.645885,"eighty":-6.415921,"marketCap":5851505250},{"date":"2023-08-11","current":-8.062915,"twenty":-7.354402,"median":-6.732662,"eighty":-6.423028,"marketCap":6826756125},{"date":"2023-08-18","current":-6.496848,"twenty":-7.428921,"median":-6.729682,"eighty":-6.45189,"marketCap":5461404900},{"date":"2023-08-25","current":-8.440637,"twenty":-7.525288,"median":-6.804775,"eighty":-6.49752,"marketCap":6327427677},{"date":"2023-09-01","current":-9.089804,"twenty":-8.007442,"median":-6.902032,"eighty":-6.501491,"marketCap":6842360139},{"date":"2023-09-08","current":-6.586545,"twenty":-8.136633,"median":-6.907229,"eighty":-6.507456,"marketCap":4899660396},{"date":"2023-09-15","current":-5.932237,"twenty":-8.007442,"median":-6.869978,"eighty":-6.423028,"marketCap":4447143990},{"date":"2023-09-22","current":-6.606383,"twenty":-7.784235,"median":-6.883282,"eighty":-6.45189,"marketCap":4930868424},{"date":"2023-09-29","current":-7.14814,"twenty":-7.744431,"median":-6.894516,"eighty":-6.45189,"marketCap":5344374795},{"date":"2023-10-06","current":-7.631816,"twenty":-7.631816,"median":-6.912426,"eighty":-6.496848,"marketCap":5703267117},{"date":"2023-10-13","current":-8.856112,"twenty":-8.155063,"median":-6.923868,"eighty":-6.50021,"marketCap":6608299929},{"date":"2023-10-20","current":-8.199572,"twenty":-8.313082,"median":-7.000277,"eighty":-6.506614,"marketCap":6108971481},{"date":"2023-10-27","current":-9.816471,"twenty":-8.453817,"median":-7.029823,"eighty":-6.509983,"marketCap":7310480559},{"date":"2023-11-03","current":-11.65035,"twenty":-8.539495,"median":-7.190868,"eighty":-6.562195,"marketCap":8699237805},{"date":"2023-11-10","current":-10.973476,"twenty":-8.805599,"median":-7.285091,"eighty":-6.584244,"marketCap":8192107350},{"date":"2023-11-17","current":-11.729885,"twenty":-9.08956,"median":-7.4166,"eighty":-6.600627,"marketCap":8835772927},{"date":"2023-11-24","current":-11.685472,"twenty":-9.394133,"median":-7.490817,"eighty":-6.605936,"marketCap":8874782962},{"date":"2023-12-01","current":-9.84176,"twenty":-10.15546,"median":-7.577915,"eighty":-6.610422,"marketCap":7505530734},{"date":"2023-12-08","current":-7.796477,"twenty":-9.900606,"median":-7.778973,"eighty":-6.615093,"marketCap":5921723313},{"date":"2023-12-15","current":-9.518573,"twenty":-9.821529,"median":-7.782262,"eighty":-6.63353,"marketCap":7271470524},{"date":"2023-12-22","current":-9.095699,"twenty":-9.838318,"median":-7.864399,"eighty":-6.64429,"marketCap":6943786230},{"date":"2023-12-29","current":-10.114857,"twenty":-10.007865,"median":-8.108989,"eighty":-6.673018,"marketCap":7762996965},{"date":"2024-01-05","current":-7.064143,"twenty":-9.846254,"median":-7.963657,"eighty":-6.71691,"marketCap":5383384830},{"date":"2024-01-12","current":-6.507833,"twenty":-9.8409,"median":-7.785551,"eighty":-6.71691,"marketCap":4962076452},{"date":"2024-01-19","current":-6.147909,"twenty":-9.833261,"median":-7.674627,"eighty":-6.639506,"marketCap":4681204200},{"date":"2024-01-26","current":-4.037471,"twenty":-9.789285,"median":-7.606263,"eighty":-6.604594,"marketCap":3062287747},{"date":"2024-02-02","current":-1.910591,"twenty":-9.668744,"median":-7.523229,"eighty":-6.508431,"marketCap":1447272298},{"date":"2024-02-09","current":-1.972972,"twenty":-9.600955,"median":-7.449769,"eighty":-6.45189,"marketCap":1501886347},{"date":"2024-02-16","current":-2.11088,"twenty":-9.539168,"median":-7.4166,"eighty":-6.417948,"marketCap":1607213442},{"date":"2024-02-23","current":-1.782124,"twenty":-9.334553,"median":-7.285091,"eighty":-6.285716,"marketCap":1349747211},{"date":"2024-03-01","current":-3.73704,"twenty":-9.184661,"median":-7.220535,"eighty":-6.16588,"marketCap":2832128541},{"date":"2024-03-08","current":-3.812556,"twenty":-9.158571,"median":-7.14814,"eighty":-5.783471,"marketCap":2890643593},{"date":"2024-03-15","current":-3.774736,"twenty":-9.108268,"median":-7.054895,"eighty":-5.122231,"marketCap":2859435565},{"date":"2024-03-22","current":-3.314294,"twenty":-9.090983,"median":-7.029823,"eighty":-4.16949,"marketCap":2508345250},{"date":"2024-03-28","current":-5.557677,"twenty":-9.089621,"median":-7.000277,"eighty":-4.108477,"marketCap":2219670991},{"date":"2024-04-05","current":-4.994454,"twenty":-9.061533,"median":-6.958518,"eighty":-4.159233,"marketCap":1993412788},{"date":"2024-04-12","current":-4.698569,"twenty":-8.939101,"median":-6.914215,"eighty":-4.187247,"marketCap":1876382683},{"date":"2024-04-19","current":-5.074098,"twenty":-8.895252,"median":-6.907229,"eighty":-4.270544,"marketCap":2024620816},{"date":"2024-04-26","current":-6.049449,"twenty":-8.886537,"median":-6.872048,"eighty":-4.439166,"marketCap":2410820163},{"date":"2024-05-03","current":-6.122202,"twenty":-8.8768,"median":-6.815159,"eighty":-4.698569,"marketCap":2438127187},{"date":"2024-05-10","current":-6.43996,"twenty":-8.86224,"median":-6.755587,"eighty":-4.994454,"marketCap":2570761306},{"date":"2024-05-17","current":-7.203002,"twenty":-8.857338,"median":-6.782134,"eighty":-5.0499,"marketCap":2871138576},{"date":"2024-05-24","current":-4.794357,"twenty":-8.851703,"median":-6.739573,"eighty":-4.885401,"marketCap":2754108471},{"date":"2024-05-31","current":-4.572395,"twenty":-8.804497,"median":-6.721699,"eighty":-4.757241,"marketCap":2629276359},{"date":"2024-06-07","current":-4.421848,"twenty":-8.685949,"median":-6.645885,"eighty":-4.615745,"marketCap":2539553278},{"date":"2024-06-14","current":-3.882014,"twenty":-8.64394,"median":-6.616008,"eighty":-4.537135,"marketCap":2227472998},{"date":"2024-06-21","current":-3.862906,"twenty":-8.598267,"median":-6.605265,"eighty":-4.402835,"marketCap":2211868984},{"date":"2024-06-28","current":-3.550986,"twenty":-8.56584,"median":-6.575038,"eighty":-4.108477,"marketCap":2032422823},{"date":"2024-07-05","current":-3.292704,"twenty":-8.553381,"median":-6.507833,"eighty":-3.906941,"marketCap":1884184690},{"date":"2024-07-12","current":-3.669077,"twenty":-8.541472,"median":-6.498529,"eighty":-3.863311,"marketCap":2102640886},{"date":"2024-07-19","current":-2.927038,"twenty":-8.530589,"median":-6.44065,"eighty":-3.81922,"marketCap":1677431505},{"date":"2024-07-26","current":-2.773786,"twenty":-8.516747,"median":-6.41868,"eighty":-3.760814,"marketCap":1595510431},{"date":"2024-08-02","current":-3.12148,"twenty":-8.510893,"median":-6.387862,"eighty":-3.652511,"marketCap":1794461610},{"date":"2024-08-09","current":-2.9997,"twenty":-8.480176,"median":-6.325017,"eighty":-3.53511,"marketCap":1735946557},{"date":"2024-08-16","current":-3.214159,"twenty":-8.413826,"median":-6.28512,"eighty":-3.427,"marketCap":1860778669},{"date":"2024-08-23","current":-6.604067,"twenty":-8.372166,"median":-6.272718,"eighty":-3.478589,"marketCap":2129947911},{"date":"2024-08-30","current":-6.163541,"twenty":-8.347233,"median":-6.28512,"eighty":-3.497821,"marketCap":2001214795},{"date":"2024-09-06","current":-5.314921,"twenty":-8.300967,"median":-6.252611,"eighty":-3.516857,"marketCap":1726510663},{"date":"2024-09-13","current":-5.032211,"twenty":-8.277822,"median":-6.194778,"eighty":-3.53511,"marketCap":1630395636},{"date":"2024-09-20","current":-5.111432,"twenty":-8.256206,"median":-6.170373,"eighty":-3.56099,"marketCap":1665993794},{"date":"2024-09-27","current":-6.057967,"twenty":-8.195708,"median":-6.135055,"eighty":-3.605108,"marketCap":1986377216},{"date":"2024-10-04","current":-7.03444,"twenty":-8.180254,"median":-6.166957,"eighty":-3.621517,"marketCap":2296081191},{"date":"2024-10-10","current":-6.311883,"twenty":-8.160101,"median":-6.193894,"eighty":-3.641637,"marketCap":2046894085},{"date":"2024-10-18","current":-9.026405,"twenty":-8.160101,"median":-6.241014,"eighty":-3.658355,"marketCap":2911929324},{"date":"2024-10-25","current":-10.329157,"twenty":-8.288852,"median":-6.25781,"eighty":-3.667517,"marketCap":3331987588},{"date":"2024-11-01","current":-10.068556,"twenty":-8.453817,"median":-6.28512,"eighty":-3.723447,"marketCap":3250111825},{"date":"2024-11-08","current":-11.890039,"twenty":-8.539495,"median":-6.303819,"eighty":-3.748634,"marketCap":3809002906},{"date":"2024-11-15","current":-12.473246,"twenty":-8.638855,"median":-6.337113,"eighty":-3.770095,"marketCap":3965634801},{"date":"2024-11-22","current":-15.548537,"twenty":-8.857338,"median":-6.401271,"eighty":-3.792036,"marketCap":4941024330},{"date":"2024-11-29","current":-16.918042,"twenty":-8.907392,"median":-6.418623,"eighty":-3.798946,"marketCap":5372620800},{"date":"2024-12-06","current":-17.028741,"twenty":-9.08956,"median":-6.440305,"eighty":-3.809963,"marketCap":5395037855},{"date":"2024-12-13","current":-14.037501,"twenty":-9.184661,"median":-6.496848,"eighty":-3.825885,"marketCap":4438576850},{"date":"2024-12-20","current":-10.693671,"twenty":-9.519989,"median":-6.507224,"eighty":-3.843767,"marketCap":3366294395},{"date":"2024-12-27","current":-10.761363,"twenty":-9.613258,"median":-6.510825,"eighty":-3.853605,"marketCap":3384975274},{"date":"2025-01-03","current":-12.815569,"twenty":-9.789285,"median":-6.563121,"eighty":-3.862906,"marketCap":4035069864},{"date":"2025-01-10","current":-14.889249,"twenty":-9.925093,"median":-6.595306,"eighty":-3.863109,"marketCap":4670219750},{"date":"2025-01-17","current":-11.842286,"twenty":-10.213871,"median":-6.606383,"eighty":-3.864484,"marketCap":3717494921},{"date":"2025-01-24","current":-10.786847,"twenty":-10.358151,"median":-6.624251,"eighty":-3.867614,"marketCap":3407392329},{"date":"2025-01-28","current":-10.88357,"twenty":-10.395234,"median":-6.635203,"eighty":-3.869357,"marketCap":3455962615},{"date":"2025-02-07","current":-10.247352,"twenty":-10.395234,"median":-6.668158,"eighty":-3.877648,"marketCap":3235528242},{"date":"2025-02-14","current":-10.714001,"twenty":-10.679993,"median":-6.721699,"eighty":-3.919404,"marketCap":3381239099},{"date":"2025-02-21","current":-14.934496,"twenty":-10.737429,"median":-6.739573,"eighty":-3.995096,"marketCap":4729998562},{"date":"2025-02-28","current":-14.81818,"twenty":-10.833722,"median":-6.801774,"eighty":-4.034059,"marketCap":4677692101},{"date":"2025-03-07","current":-17.375919,"twenty":-11.045086,"median":-6.869978,"eighty":-4.108477,"marketCap":5507123129},{"date":"2025-03-14","current":-16.002657,"twenty":-11.141514,"median":-6.898274,"eighty":-4.166071,"marketCap":5073726736},{"date":"2025-03-21","current":-15.584553,"twenty":-11.292034,"median":-6.914215,"eighty":-4.215924,"marketCap":4939224407},{"date":"2025-03-28","current":-19.960729,"twenty":-11.418322,"median":-6.958518,"eighty":-4.322429,"marketCap":5432399613},{"date":"2025-04-03","current":-17.71685,"twenty":-11.522026,"median":-7.011873,"eighty":-4.393328,"marketCap":4812194430},{"date":"2025-04-11","current":-14.733536,"twenty":-11.702518,"median":-7.03444,"eighty":-4.445369,"marketCap":3975291051},{"date":"2025-04-17","current":-15.831036,"twenty":-11.83884,"median":-7.042573,"eighty":-4.481028,"marketCap":4281657466},{"date":"2025-04-25","current":-18.85387,"twenty":-11.890039,"median":-7.064143,"eighty":-4.482534,"marketCap":5103616142},{"date":"2025-05-02","current":-20.273816,"twenty":-12.024603,"median":-7.138152,"eighty":-4.483904,"marketCap":5499650777},{"date":"2025-05-09","current":-20.37867,"twenty":-12.272607,"median":-7.171338,"eighty":-4.537135,"marketCap":5566901942},{"date":"2025-05-16","current":-19.209634,"twenty":-12.535336,"median":-7.205238,"eighty":-4.575802,"marketCap":5290424932},{"date":"2025-05-23","current":-24.021586,"twenty":-12.71305,"median":-7.273665,"eighty":-4.590948,"marketCap":6635448220},{"date":"2025-05-30","current":-24.266566,"twenty":-12.811921,"median":-7.298393,"eighty":-4.611692,"marketCap":6732588791},{"date":"2025-06-06","current":-26.139049,"twenty":-13.04892,"median":-7.396066,"eighty":-4.640938,"marketCap":7270598106},{"date":"2025-06-13","current":-29.74055,"twenty":-13.19671,"median":-7.470293,"eighty":-4.681154,"marketCap":8275629397},{"date":"2025-06-20","current":-28.050034,"twenty":-13.86335,"median":-7.533906,"eighty":-4.700982,"marketCap":7789926543},{"date":"2025-06-27","current":-24.148232,"twenty":-14.651862,"median":-7.597268,"eighty":-4.71884,"marketCap":6725116440},{"date":"2025-07-04","current":-23.234874,"twenty":-14.895898,"median":-7.634748,"eighty":-4.738772,"marketCap":6471056485},{"date":"2025-07-11","current":-22.291445,"twenty":-15.089879,"median":-7.696392,"eighty":-4.760215,"marketCap":6202051828},{"date":"2025-07-18","current":-26.31753,"twenty":-15.471722,"median":-7.782262,"eighty":-4.775945,"marketCap":7316474020},{"date":"2025-07-25","current":-25.476909,"twenty":-15.613487,"median":-7.864399,"eighty":-4.786942,"marketCap":7108532126},{"date":"2025-08-01","current":-24.329935,"twenty":-15.664049,"median":-8.108989,"eighty":-4.797184,"marketCap":6746559201},{"date":"2025-08-08","current":-25.903798,"twenty":-15.966112,"median":-8.199572,"eighty":-4.803824,"marketCap":7200950746},{"date":"2025-08-15","current":-26.404653,"twenty":-16.351868,"median":-8.297938,"eighty":-4.809409,"marketCap":6923694888},{"date":"2025-08-22","current":-24.957996,"twenty":-16.76437,"median":-8.37361,"eighty":-4.821672,"marketCap":6523837408},{"date":"2025-08-25","current":-24.093478,"twenty":-16.858738,"median":-8.407124,"eighty":-4.826315,"marketCap":6322695243}],"updateTime":1756186927627},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02105\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542055259","title":"中信证券：首予来凯医药-B(02105)“买入”评级 目标价27港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542055259","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542055259?lang=zh_cn&edition=fundamental","pubTime":"2025-06-12 09:33","pubTimestamp":1749692028,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信证券发布研报称，参考相对估值与绝对估值，给予来凯医药-B2025年目标价27港元，首次覆盖，给予“买入”评级。核心产品LAE102是一款靶向ActRIIA的抗体，在临床前模型中展现出促进肌肉再生及减少脂肪的作用，有望成为实现高质量体重控制的候选药物。目前LAE102正在国内进行MAD研究，并和礼来合作在美国开展临床I期试验。公司的LAE102正处于3期注册性临床研究阶段，用于治疗HR+/HER2-晚期乳腺癌，有望成为全球第二款上市的AKT抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1304255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02105"],"gpt_icon":0},{"id":"2542554493","title":"来凯医药-B盘中异动 股价大跌5.87%报20.850港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542554493","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542554493?lang=zh_cn&edition=fundamental","pubTime":"2025-06-12 09:30","pubTimestamp":1749691808,"startTime":"0","endTime":"0","summary":"2025年06月12日早盘09时30分，来凯医药-B股票出现异动，股价快速下跌5.87%。截至发稿，该股报20.850港元/股，成交量4.8万股，换手率0.01%，振幅4.51%。资金方面，该股资金流入10.39万港元，流出62.8475万港元。来凯医药-B股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，中国抗体-B、维亚生物、晶泰控股涨幅较大，振幅较大的相关个股有来凯医药-B、科济药业-B、中国抗体-B，振幅分别为2.93%、2.78%、2.47%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506120930089518aa66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506120930089518aa66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2542058825","title":"每日卖空追踪 | 来凯医药-B 06月11日卖空量成交1.85万股，卖空比例为0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542058825","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542058825?lang=zh_cn&edition=fundamental","pubTime":"2025-06-11 16:30","pubTimestamp":1749630627,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间06月11日，涨0.23%，卖空量成交1.85万股%，较上一交易日减少68.38%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611175305a4a350fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611175305a4a350fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2542340371","title":"“吃药”行情继续，减肥药概念逆势大涨！","url":"https://stock-news.laohu8.com/highlight/detail?id=2542340371","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542340371?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 18:41","pubTimestamp":1749552086,"startTime":"0","endTime":"0","summary":"6月10日，“吃药”行情继续，减肥药板块逆势上扬，成为两市为数不多的强势板块之一。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202506_1/e8b89cf9-e081-438d-a567-fab4e98dbc00.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202506_1/e8b89cf9-e081-438d-a567-fab4e98dbc00.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/68480bd65a7712f1b9b39d46","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["LU2237443465.HKD","LU0742534661.SGD","LU1791807156.HKD","LU2237443549.SGD","LU1894683348.USD","LU2237443622.USD","LU0251142724.SGD","LU2471134796.USD","LU0048573561.USD","IE00BFXG1179.USD","02105","LU1868837136.USD","LU2237443978.SGD","LU2471134523.USD","IE00B19Z3581.USD","BK4588","LU0251131958.USD","IE00BSNM7G36.USD","BK4533","IE0004091025.USD","LU1868837300.USD","BK4516","LU1868836757.USD","LU0061475181.USD","IE0002270589.USD","IE0034235188.USD","LU2750360641.GBP","LU2237443895.HKD","BK4550","LU2471134879.HKD","BK4585","LU2237443382.USD","BK4552","BK4127","LU1868836591.USD","IE0004086264.USD","LU2237438978.USD","LU1894683264.USD","BK1161","LU1668664300.SGD","BK4504","LU0106831901.USD","LU1868836914.USD","LU2471134952.CNY","LU2750360997.AUD","IE00B19Z3B42.SGD","LU0096364046.USD"],"gpt_icon":0},{"id":"2542853833","title":"每日卖空追踪 | 来凯医药-B 06月09日卖空量成交8.85万股，卖空比例为0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542853833","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542853833?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 16:30","pubTimestamp":1749457828,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间06月09日，涨13.82%，卖空量成交8.85万股%，较上一交易日增加20.41%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609175117a4a02e63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609175117a4a02e63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2542806906","title":"来凯医药-B尾盘涨超13% LAE102的I期SAD研究结果可观 与礼来合作有望增强国际影响力","url":"https://stock-news.laohu8.com/highlight/detail?id=2542806906","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542806906?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 15:57","pubTimestamp":1749455836,"startTime":"0","endTime":"0","summary":"2024年11月20日，公司发布公告，与礼来就LAE102针对肥胖症治疗在美国开展临床合作；今年3月26日，公司发布公告，LAE102肥胖症的I期临床完成MAD研究首例受试者访视。中信建投认为，LAE102具有优秀的药理性，在I期SAD临床研究中展现出良好的疗效和安全性，为I期MAD研究打下良好基础；与礼来的合作标志着公司的国际影响力进一步增强；公司的I期SAD临床试验数据和后续临床试验值得关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609160541a70035e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609160541a70035e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2023250504.SGD","LU0320765992.SGD","LU0198837287.USD","LU2461242641.AUD","LU0354030511.USD","LU2552382058.USD","SG9999001176.SGD","SGXZ81514606.USD","LU2237438978.USD","LU2552382132.HKD","LU0266013472.USD","SG9999001176.USD","LU2471134796.USD","LU2750360997.AUD","LU2236285917.USD","LU1280957306.USD","IE0004445239.USD","LU0079474960.USD","SG9999014914.USD","LU1366192091.USD","IE00BFTCPJ56.SGD","LU0786609619.USD","BK4534","LU1127390331.HKD","SGXZ57979304.SGD","LU0234572021.USD","SG9999015986.USD","LU1868836591.USD","LLY","SG9999018857.SGD","LU1720051108.HKD","IE0009355771.USD","LU0323591593.USD","LU2491049909.HKD","LU1988902786.USD","LU0385154629.USD","LU2361044865.SGD","LU1868836757.USD","LU0823416689.USD","LU0109391861.USD","LU1548497426.USD","LU0672654240.SGD","LU2491050154.USD","02105","LU0256863902.USD","LU2361045086.USD","IE00B4R5TH58.HKD","LU1974910355.USD","LU1814569148.SGD","LU0471298777.SGD","IE00B2B36J28.USD"],"gpt_icon":1},{"id":"2542878170","title":"来凯医药-B盘中异动 股价大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542878170","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542878170?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:30","pubTimestamp":1749432626,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时30分，来凯医药-B股票出现异动，股价大幅上涨5.34%。截至发稿，该股报20.500港元/股，成交量6.5万股，换手率0.02%，振幅4.42%。资金方面，该股资金流入78.845万港元，流出43.414万港元。来凯医药-B股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，中国抗体-B、歌礼制药-B、科济药业-B涨幅较大，振幅较大的相关个股有中国抗体-B、来凯医药-B、科济药业-B，振幅分别为4.69%、4.42%、3.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093026a49f8342&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093026a49f8342&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2541670856","title":"来凯医药-B06月06日获主力加仓122.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541670856","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541670856?lang=zh_cn&edition=fundamental","pubTime":"2025-06-06 16:15","pubTimestamp":1749197741,"startTime":"0","endTime":"0","summary":"06月06日, 来凯医药-B股价涨1.99%，报收19.46元，成交金额7077.3万元，换手率0.90%，振幅9.17%，量比0.51。来凯医药-B今日主力资金净流入122.3万元，上一交易日主力净流入5.3万元。该股近5个交易日上涨7.10%，主力资金累计净流出76.7万元；近20日主力资金累计净流出1697.3万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606173018a49cb3a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606173018a49cb3a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2541026829","title":"来凯医药-B06月05日主力净流入5.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2541026829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541026829?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 16:15","pubTimestamp":1749111340,"startTime":"0","endTime":"0","summary":"06月05日, 来凯医药-B股价涨0.10%，报收19.08元，成交金额9164.0万元，换手率1.16%，振幅7.61%，量比0.68。来凯医药-B今日主力资金净流入5.3万元，上一交易日主力净流出203.0万元。该股近5个交易日上涨11.19%，主力资金累计净流入165.0万元；近20日主力资金累计净流出557.5万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605172915a49b2ee6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605172915a49b2ee6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2540032181","title":"来凯医药-B盘中异动 临近收盘股价大跌5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540032181","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540032181?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 15:31","pubTimestamp":1749022291,"startTime":"0","endTime":"0","summary":"2025年06月04日临近收盘15时31分，来凯医药-B股票出现波动，股价急速跳水5.27%。截至发稿，该股报19.040港元/股，成交量624.8万股，换手率1.53%，振幅6.27%。来凯医药-B股票所在的生物技术行业中，整体涨幅为2.40%。其相关个股中，中国抗体-B、华领医药-B、再鼎医药涨幅较大，振幅较大的相关个股有中国抗体-B、华领医药-B、北海康成-B，振幅分别为39.50%、21.59%、15.62%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604153131a499783e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604153131a499783e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2540375712","title":"围绕ActRII通路 礼来与来凯医药(02105)将在2025ADA上“双龙戏珠”","url":"https://stock-news.laohu8.com/highlight/detail?id=2540375712","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540375712?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 09:08","pubTimestamp":1748912938,"startTime":"0","endTime":"0","summary":"令人注意的是，围绕ActRII通路，礼来的ActRIIA/B抗体Bimagurmab与司美格鲁肽联用的二期研究结果将在6月23日ADA大会上有一个半小时的专题报道，可见该数据的整体重要性。早一天，潜在国产同类最佳来凯医药的ActRIIA抗体LAE102将公布首次人体研究数据，上演一出“双龙戏珠”。好戏开演，ActRII通路正在成为巨额deal诞生的温床。ActRII通路的配体抑制开发路线创新分子，率先为赛道发声。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1300476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2491049909.HKD","LU2211815571.USD","LU0058720904.USD","IE0009355771.USD","SG9999015978.USD","LU2106854487.HKD","LU2471134952.CNY","BK4533","BK4599","LU2265009873.SGD","SG9999018857.SGD","IE00BK4W5M84.HKD","LU2360106947.USD","LU2750360641.GBP","LU1988902786.USD","LU0823416689.USD","LU0882574139.USD","LU2237443465.HKD","LU0203202063.USD","LU0889565916.HKD","LU1064131342.USD","SGXZ51526630.SGD","LU2750360997.AUD","LU0471298777.SGD","LU1093756325.SGD","LU1232071149.USD","IE0004445239.USD","BK4585","LU1868836591.USD","LLY","LU1868836914.USD","GB00BDT5M118.USD","LU2552382132.HKD","LU2552382215.SGD","SG9999013999.USD","LU1804176565.USD","LU1989771016.USD","02105","SG9999014898.SGD","LU0109391861.USD","SGXZ31699556.SGD","LU0256863811.USD","LU1280957306.USD","SG9999014906.USD","LU0203201768.USD","LU2324357040.USD","LU0079474960.USD","SGXZ99366536.SGD","LU2357305700.SGD","LU0689472784.USD"],"gpt_icon":1},{"id":"2540145237","title":"2025ADA，减脂增肌风暴压不住了","url":"https://stock-news.laohu8.com/highlight/detail?id=2540145237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540145237?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 08:40","pubTimestamp":1748911200,"startTime":"0","endTime":"0","summary":"接下来6月底的2025美国糖尿病学大会，可谓是神仙打架，聚集了一大批代表全球减重主流及差异化方向的优异管线成果，可以预见未来重磅授权交易将有十之八九出自于此。从2025年美国糖尿病学大会议程可以看到，关于Bima的专题研讨会时长有一个半小时，包括5个主题演讲、问答和小组讨论。从MNC交易思维的角度，LAE102可能成为GLP-1类药物潜在最佳的减脂增肌伴侣。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1300457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SAT","TRAE","02105","BK1161"],"gpt_icon":0},{"id":"2540769158","title":"每日卖空追踪 | 来凯医药-B 06月02日卖空量成交15.25万股，卖空比例为2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540769158","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540769158?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 16:30","pubTimestamp":1748853026,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间06月02日，涨6.33%，卖空量成交15.25万股%，较上一交易日减少67.62%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602163629a4966ba6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602163629a4966ba6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2540500387","title":"来凯医药-B涨超9% LAE102 I期SAD试验结果可观 将展示多项ActRII领域自主研发成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2540500387","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540500387?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 14:25","pubTimestamp":1748845512,"startTime":"0","endTime":"0","summary":"消息面上，来凯医药近日宣布，其自主研发针对ActRIIA的单克隆抗体LAE102，在美国针对肥胖症治疗的一项I期临床试验已完成首位受试者给药。据悉，ADA科学年会是全球糖尿病领域的顶级学术盛会，将于今年6月20日至23日在美国芝加哥召开。中信建投指出，公司核心产品LAE102的I期SAD试验结果可观，为I期MAD试验做良好铺垫，同时与礼来开展合作进一步提升国际影响力；LAE002临床试验持续推进，针对乳腺癌的III期临床试验值得关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602143448a4964a2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602143448a4964a2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2540757945","title":"来凯医药－Ｂ(02105)股价显著波动10.766%，现价港币$18.94","url":"https://stock-news.laohu8.com/highlight/detail?id=2540757945","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540757945?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 13:25","pubTimestamp":1748841900,"startTime":"0","endTime":"0","summary":"[异动股]来凯医药－Ｂ(02105) 股价在下午01:25出现显著波动10.766%，现股价为港币$18.94，比前收市价上升5.105%5.105%。至目前为止，今日最高价为$18.94，而最低价为$17.0。总成交量为243.06万股，总成交金额为港币$4.328千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112134424260_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112134424260_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC25060228/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2539281892","title":"每日卖空追踪 | 来凯医药-B 05月30日卖空量成交29.8万股，卖空比例为3.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539281892","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539281892?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 16:30","pubTimestamp":1748593827,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间05月30日，涨5.01%，卖空量成交29.8万股%，较上一交易日增加70.77%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530174856a6f322b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530174856a6f322b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2539211220","title":"来凯医药-B午前涨逾6% 公司将展示多项ActRII领域自主研发成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2539211220","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539211220?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 11:56","pubTimestamp":1748577377,"startTime":"0","endTime":"0","summary":"来凯医药-B盘中涨超6%，截至发稿，股价上涨5.94%，现报18.18港元，成交额8077.36万港元。来凯医药宣布，公司将在美国糖尿病协会第85届科学年会上，以壁报形式展示多项增肌减脂领域的研发成果——靶向ActRII的三款单克隆抗体LAE102、LAE103和LAE123的临床前数据，以及其中一款针对ActRIIA的单抗LAE102的首次人体研究数据。该机构认为，公司研发布局全球一体化，管线结构均衡，未来可期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/05/30115650761657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2539902472","title":"【券商聚焦】中信建投首予来凯医药(02105)“买入”评级 指其管线结构均衡 未来可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2539902472","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539902472?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 09:06","pubTimestamp":1748567160,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研报指，2024年，来凯医药 研发费用2.15亿元，与2023年相比保持稳定，费用管控稳健，2024年整体发展符合预期。该机构认为，公司研发布局全球一体化，管线结构均衡，未来可期。基于DCF模型，该机构预计公司2025、2026、2027年产品收入为0、0、1.69亿元，公司合理估值为93.9亿港元，给予目标价23.02港元，首次给予“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1959580","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"gpt_icon":0},{"id":"2539225638","title":"每日卖空追踪 | 来凯医药-B 05月29日卖空量成交7.5万股，卖空比例为2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539225638","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539225638?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 16:30","pubTimestamp":1748507426,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间05月29日，涨2.02%，卖空量成交7.5万股%，较上一交易日减少69.57%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529174202a4912077&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529174202a4912077&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2539236671","title":"来凯医药-B(2105.HK)：与礼来达成临床合作 公司减脂增肌赛道持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2539236671","media":"中信建投证券","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539236671?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 00:00","pubTimestamp":1748448000,"startTime":"0","endTime":"0","summary":"公司核心产品LAE102 的I 期SAD 试验结果可观，为I 期MAD 试验做良好铺垫，同时与礼来开展合作进一步提升国际影响力；LAE002 临床试验持续推进，针对乳腺癌的III 期临床试验值得关注。2025 年3 月26 日，公司发布公告，LAE102 肥胖症的I 期临床完成MAD 研究首例受试者访视。2024 年11 月，公司与礼来签订临床合作协议，礼来将负责在美国执行一项I 期研究并承担相关费用，美国I 期临床试验预计于2025 年第二季度开始。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529133117a6f15422&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529133117a6f15422&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":194,"code":"91000000","status":"200"}]}}